Molecular Mechanisms by which Statins Prevent and Reverse Hepatocellular Carcinoma
他汀类药物预防和逆转肝细胞癌的分子机制
基本信息
- 批准号:10856787
- 负责人:
- 金额:$ 34.19万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-09-19 至 2027-08-31
- 项目状态:未结题
- 来源:
- 关键词:Biological MarkersBloodCancer EtiologyCellular Metabolic ProcessCholestasisCholesterolCirrhosisClinicalClinical ResearchClinical TrialsCohort StudiesCollaborationsCompensationCryptogenic cirrhosisCytometryDiagnosticEtiologyFatty AcidsFibrosisGastroenterologyGlucoseGlutamineHepaticHepatologyHomeostasisHumanHydroxymethylglutaryl-CoA Reductase InhibitorsImmuneImmune systemImmunologic MarkersImmunologic SurveillanceInflammationKnowledgeLaboratoriesLeadLettersLibrariesLipidsLiver CirrhosisLiver diseasesMYC geneMalignant NeoplasmsMass Spectrum AnalysisMediatingMedical OncologyMeta-AnalysisMetabolicMetabolic PathwayMetabolismModelingMolecularNational Institute of Diabetes and Digestive and Kidney DiseasesNatureOncologyOxidative StressOxidoreductasePathogenesisPathway interactionsPatientsPharmaceutical PreparationsPhosphorylationPreventionPreventivePreventive therapyPrimary carcinoma of the liver cellsProliferatingPropertyPublishingReportingResearchResearch PersonnelRiskRisk ReductionSamplingSeriesSignal TransductionSystemTetanus Helper PeptideTherapeutic EffectTransgenic MiceTransgenic ModelTransgenic OrganismsTravelTumor Suppressor GenesUnited States National Institutes of HealthWorkanti-canceranticancer researchatorvastatinbiomarker identificationcancer therapycarcinogenesiscytokineepidemiology studyfightingimaging agentimprovedinhibitorinsightionizationlipid biosynthesisliver cancer modelmass spectrometric imagingmembermetabolomicsmortalitymouse modelnon-alcoholic fatty liver diseasenonalcoholic steatohepatitisnovelnovel therapeuticspatient derived xenograft modelpre-clinicalpreventprogramsprospectiverosuvastatinsingle-cell RNA sequencingtumortumor immunologytumor initiationtumor progressiontumorigenesis
项目摘要
Project Summary/Abstract
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide. HMG-CoA
reductase (HMGCR) inhibitors, statins, show high potential in the prevention and treatment of cancer including
HCC. We will investigate the mechanism by which statins fight against HCC and discovering the biomarkers to
predict the therapeutic effects. Through our previously published work, we have used our conditional transgenic
mouse models of HCC to identify a novel pathway that statins suppress MYC signaling to execute the anti-cancer
properties. Also, we identified that MYC rewires metabolic pathways to promote fatty acid synthesis in addition
to glucose and glutamine pathways. Inhibition of fatty acid synthesis by TOFA elicits dramatic regression of MYC
driven tumors and the efficacy correlates to MYC level. Statin (e.g., Atorvastatin) blocks MYC phosphorylation in
our MYC-driven HCC model and inhibit tumor initiation and progression (see our Preliminary Results). We
hypothesize that the MYC pathway is suppressed by statins and this is a mechanism by which statins can prevent
and treat HCC, both through direct anti-oncogene effects as well as by restoring immune surveillance. We will
determine the mechanisms by which statins protect against HCC, we propose to 1) evaluate the anti-cancer
efficacy of statins at different progression stages of MYC driven HCC (before MYC induction, early stage of
tumorigenesis, late stage of HCC) and the condition of association with NASH; 2) identify specific metabolism
pathways regulated by statin in MYC-HCC; 3) define the changes of immune system and specific
effectors/cytokines influenced by statin; 4) discover the biomarkers that can predict the therapeutic effect of statin
in prevention of HCC. Our team includes expertise in Medical Oncology, the MYC oncogene and Tumor
Immunology (Felsher), Gastroenterology and HCC (Dhanasekaran) and Hepatology and liver disease (Verna
and Brown). Dr. Verna and Dr. Brown are members of the Liver Cirrhosis Network (LCN) clinical program (RAF-
CA-23-023) and are currently investigating the effect of lipid lowing medications (Statins) in patients with
compensated NASH, ALD, cholestatic and cryptogenic cirrhosis. The LCN study provides us with a unique
opportunity to identify mechanisms through use of our preclinical transgenic mouse model of HCC that can be
evaluated using human clinical samples to available to us through the LCN. Our work will help identify lead to
the identification of the mechanisms by which statins can block HCC as well as identify biomarkers that can
predict when these agents are most likely to be useful in preventing HCC.
项目概要/摘要
肝细胞癌(HCC)是全球癌症相关死亡的主要原因。 HMG辅酶A
还原酶 (HMGCR) 抑制剂他汀类药物在预防和治疗癌症方面显示出巨大潜力,包括
肝癌。我们将研究他汀类药物对抗 HCC 的机制并发现生物标志物
预测治疗效果。通过我们之前发表的工作,我们使用了我们的有条件转基因
HCC 小鼠模型确定他汀类药物抑制 MYC 信号传导以执行抗癌作用的新途径
特性。此外,我们还发现 MYC 重新连接代谢途径以促进脂肪酸合成
葡萄糖和谷氨酰胺途径。 TOFA 抑制脂肪酸合成可引起 MYC 急剧消退
驱动肿瘤,疗效与 MYC 水平相关。他汀类药物(例如阿托伐他汀)可阻断 MYC 磷酸化
我们的 MYC 驱动的 HCC 模型并抑制肿瘤的发生和进展(参见我们的初步结果)。我们
假设 MYC 通路被他汀类药物抑制,这是他汀类药物可以预防的一种机制
通过直接抗癌基因作用以及恢复免疫监视来治疗肝癌。我们将
为了确定他汀类药物预防 HCC 的机制,我们建议 1) 评估其抗癌作用
他汀类药物在 MYC 驱动的 HCC 不同进展阶段(MYC 诱导前、早期阶段)的疗效
肿瘤发生、HCC 晚期)以及与 NASH 相关的状况; 2)确定特定的代谢
MYC-HCC 中他汀类药物调节的途径; 3)定义免疫系统的变化和具体
受他汀类药物影响的效应子/细胞因子; 4)发现可以预测他汀类药物治疗效果的生物标志物
预防肝癌。我们的团队拥有肿瘤内科、MYC 癌基因和肿瘤方面的专业知识
免疫学 (Felsher)、胃肠病学和 HCC (Dhanasekaran) 以及肝病学和肝病 (Verna)
和布朗)。 Verna 博士和 Brown 博士是肝硬化网络 (LCN) 临床计划 (RAF-
CA-23-023),目前正在研究降脂药物(他汀类药物)对患有以下疾病的患者的影响:
代偿性 NASH、ALD、胆汁淤积性和隐源性肝硬化。 LCN 研究为我们提供了独特的
通过使用我们的临床前转基因小鼠 HCC 模型来确定机制的机会
使用人类临床样本进行评估,并通过 LCN 向我们提供。我们的工作将有助于确定导致
鉴定他汀类药物阻断 HCC 的机制以及鉴定可预防 HCC 的生物标志物
预测这些药物何时最有可能有助于预防 HCC。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DEAN W FELSHER其他文献
DEAN W FELSHER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DEAN W FELSHER', 18)}}的其他基金
Targeting the MYC Pathway for the Treatment of Cancer
靶向 MYC 通路治疗癌症
- 批准号:
10463750 - 财政年份:2020
- 资助金额:
$ 34.19万 - 项目类别:
Targeting the MYC Pathway for the Treatment of Cancer
靶向 MYC 通路治疗癌症
- 批准号:
10693915 - 财政年份:2020
- 资助金额:
$ 34.19万 - 项目类别:
Targeting the MYC Pathway for the Treatment of Cancer
靶向 MYC 通路治疗癌症
- 批准号:
10256047 - 财政年份:2020
- 资助金额:
$ 34.19万 - 项目类别:
Targeting the MYC Pathway for the Treatment of Cancer
靶向 MYC 通路治疗癌症
- 批准号:
10053533 - 财政年份:2020
- 资助金额:
$ 34.19万 - 项目类别:
(PQ7)Multi-scale Analysis of Tumor Microenvironment Heterogeneity
(PQ7)肿瘤微环境异质性多尺度分析
- 批准号:
9378269 - 财政年份:2017
- 资助金额:
$ 34.19万 - 项目类别:
Cancer-Translational Nanotechnology Training Program (Cancer-TNT)
癌症转化纳米技术培训计划(Cancer-TNT)
- 批准号:
8934256 - 财政年份:2015
- 资助金额:
$ 34.19万 - 项目类别:
Cancer-Translational Nanotechnology Training Program (Cancer-TNT)
癌症转化纳米技术培训计划(Cancer-TNT)
- 批准号:
9443842 - 财政年份:2015
- 资助金额:
$ 34.19万 - 项目类别:
Cancer-Translational Nanotechnology Training Program (Cancer-TNT)
癌症转化纳米技术培训计划(Cancer-TNT)
- 批准号:
9321153 - 财政年份:2015
- 资助金额:
$ 34.19万 - 项目类别:
Prognostic Metabolic Signatures of Cancers Through Mass Spectrometry Imaging
通过质谱成像预测癌症的代谢特征
- 批准号:
8673796 - 财政年份:2014
- 资助金额:
$ 34.19万 - 项目类别:
Modeling and Predicting Therapeutic Resistance of Cancer
癌症治疗耐药性的建模和预测
- 批准号:
8766569 - 财政年份:2014
- 资助金额:
$ 34.19万 - 项目类别:
相似海外基金
Open Access Block Award 2024 - NHS Blood and Transplant NHSBT School
2024 年开放获取块奖 - NHS 血液和移植 NHSBT 学校
- 批准号:
EP/Z532551/1 - 财政年份:2024
- 资助金额:
$ 34.19万 - 项目类别:
Research Grant
The role of dietary and blood proteins in the prevention and development of major age-related diseases
膳食和血液蛋白在预防和发展主要与年龄相关的疾病中的作用
- 批准号:
MR/X032809/1 - 财政年份:2024
- 资助金额:
$ 34.19万 - 项目类别:
Fellowship
A cluster randomized controlled trial to evaluate pharmacy-based health promotion program to improve blood pressure control in Bangladesh, India and Pakistan
一项整群随机对照试验,旨在评估孟加拉国、印度和巴基斯坦基于药房的健康促进计划,以改善血压控制
- 批准号:
23K24566 - 财政年份:2024
- 资助金额:
$ 34.19万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
経胸壁心臓超音波のBlood Speckle Imagingを用いた大動脈弓部病変評価の研究
经胸心脏超声血斑成像评价主动脉弓病变的研究
- 批准号:
24K10591 - 财政年份:2024
- 资助金额:
$ 34.19万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
STTR Phase I: A Completely Non-Toxic Blood Bag That Keeps Blood Healthier, Longer
STTR 第一阶段:完全无毒的血袋,使血液保持更健康、更长久
- 批准号:
2335363 - 财政年份:2024
- 资助金额:
$ 34.19万 - 项目类别:
Standard Grant
How blood vessel stiffness regulates their growth and maintenance
血管硬度如何调节其生长和维持
- 批准号:
DE240101055 - 财政年份:2024
- 资助金额:
$ 34.19万 - 项目类别:
Discovery Early Career Researcher Award
Engaging the over 50s to ensure the sustainability of our blood supply
让 50 多岁的人参与进来,确保我们血液供应的可持续性
- 批准号:
LP220200819 - 财政年份:2024
- 资助金额:
$ 34.19万 - 项目类别:
Linkage Projects
A methodology to connect functionalized gonadal constructs to a chick embryo through mechanically induced blood vessels from an egg
一种通过鸡蛋机械诱导血管将功能化性腺结构连接到鸡胚胎的方法
- 批准号:
24K15741 - 财政年份:2024
- 资助金额:
$ 34.19万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Defining a new mechanism of blood pressure regulation and its role during sepsis
定义血压调节的新机制及其在脓毒症期间的作用
- 批准号:
MR/Y011805/1 - 财政年份:2024
- 资助金额:
$ 34.19万 - 项目类别:
Research Grant
Designing and fabricating artificial blood cells for global shortages
设计和制造人造血细胞应对全球短缺
- 批准号:
DE240100236 - 财政年份:2024
- 资助金额:
$ 34.19万 - 项目类别:
Discovery Early Career Researcher Award














{{item.name}}会员




